efp*****a



Innovative Medicines Initiative

Joining and contributing to IMI activities

IMI2 vision – towards integrated healthcare solutions

- * Addressing healthcare priorities identified by the WHO 2013 report
- * Strategic Research Agenda aimed at progressing the vision of stratified medicines: prevention, treatment and health management
- * Entire product cycle from discovery, through development to healthcare delivery and access models
- * Collaboration across sectors to harness all knowledge and technologies which can contribute to IMI2 vision diagnostics, imaging, IT, medical devices, ...



IMI2: for integrated healthcare solutions

- * Focus: stratified medicines and healthcare priorities
- Integrated solutions:
 prevention and treatment
- * End-to-end agenda: R&D, regulatory, access/healthcare practice
- *** Multi-sector:** within and beyond life sciences

Cash for public partners



European Commission From H2020

1638 mln

Contributing own resource



EFPIA direct and indirect members


1425 mln

Others 213 mln



EFPIA direct or indirect member

IMI2 total budget €3.28 bn





EFPIA direct or indirect member


- * Affiliated entities of an EFPIA corporate member, EFPIA specialized group (Vaccines Europe or EBE)
- * Member of an EFPIA member association
- * EFPIA Partner in Research, mainly commercial organisations
 - * Non-pharmaceutical companies, e.g. imaging, medical information technology, diagnostic, animal health industries,

. . .

- * To date: GE HealthCare, Zeiss, Zoetis, PMB Alcen, Alcediag
- * Contact: magda.chlebus@efpia.eu & katharina.angrosch@efpia.eu



Current focus: From idea to topic and budget



- Any company or SGG may propose a topic
- All proposals are reviewed by the RDG against industry priorities

- 3rd parties can submit proposals through Efpia website (on line form)
- If supported by the RDG <u>or</u> SGG, the idea may be incorporated into an IMI2 project
- 3 months for decision and feedback



Strategic Governing Groups

Immunology

Lead: GSK

AbbVie. Almirall. Amgen, Astellas, AZ, Bayer, Biogen Idec. Boehringer Ingelheim, GSK. Janssen. Merck, MSD, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi Pasteur. Takeda, UCB. Vifor Pharma

Diabetes & Metabolic Disorders

Lead: Sanofi, co-lead: Eli Lilly, Servier

Amgen, AZ, Boehringer Ingelheim, Eli Lilly, GSK, Janssen, MSD, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier

Neurodegeration

Lead: Janssen, colead: Eli Lilly, Abbvie

AbbVie, AZ, Biogen Idec, Boehringer Ingelheim, EISAI, Eli Lilly, GSK, Grünenthal, Ipsen, Janssen, Lundbeck, Merck, MSD, Novartis, Orion, Pfizer, Roche, Sanofi, Servier, UCB

Translational safety

Lead: Sanofi, co-leads: Bayer, Janssen, Novartis

AbbVie, AZ, Bayer, Boehringer Ingelheim, Eli Lilly, GSK, Janssen, Merck, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi, Servier, UCB, Vifor Pharma

Data & Knowledge Management

Lead: Janssen, colead: Pfizer

Astellas, AZ, Bayer, Daiichi-Sankyo, Genzyme, GSK, Grünenthal, Janssen, MSD, Novo Nordisk, Pfizer, Roche, Sanofi, Servier, UCB

Infections control


Leads: AZ/Medimmune

AiCuris, Astellas, AZ, Basilea, Cubist, GSK, J&J, Pfizer (tbc), Sanofi, Vifor, Menarini (tbc), MSD, Novartis and Roche (tbc)



IMI 2 Associated Partner (1)

IMI2 total budget €3.28 bn





IMI2 Associated Partner (2)

- Any legal entity other than a Member or a constituent/affiliated entity of a Member, may apply to join IMI2 as an Associated Partner
 - Entity supporting the objectives of the IMI2 Joint Undertaking in its specific area of research;
 - Upon acceptance of the IMI2 Statutes by a letter of endorsement, that details the scope of the association in terms of contribution (in-kind or in-cash), activities and duration;
 - Application to be addressed to the IMI2 Governing Board

Mainly non-commercial organisations:

- Juvenile Diabetes Research Foundation (JDRF)
- Leona M. and Harry B. Helmsley Charitable Trust
- Bill and Melinda Gates Foundation



How to submit a proposal for a project or a scientific question?

Innovative Medicines Initiative















http://imi.efpia.eu/